Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Jan 23, 2017 • 4:30 PM EST
Ligand to Report Fourth Quarter and Full Year 2016 Results on February 23rd
Dec 22, 2016 • 9:15 AM EST
Ligand Enters Commercial License and Supply Agreements for Captisol®-enabled trametinib
Dec 22, 2016 • 8:30 AM EST
Ligand Enters into Worldwide OmniAb® Platform License Agreement with ONO PHARMACEUTICAL CO., LTD.
Nov 9, 2016 • 1:00pm EST
New York, NY
See all events
Nov 3, 2016 • 4:30pm EST
Sep 13, 2016 • 9:10am EST
New York City
Feb 23, 2017 • 4:30pm EST
Sparsentan highlighted by $RTRX at #JPM17 https://t.co/qwss47QR0P
Merck KGaA licenses Captisol-enabled VX-970 from Vertex https://t.co/QYznIgnPGc
Captisol-enabled GS-5734 highlighted by $GILD at #JPM17 https://t.co/Q5aD4fQXAE